Deepening US footprint, AstraZeneca-partnered French biotech Innate shoots for $100M IPO

Fresh off of a 20th birthday celebration, French biotech Innate Pharma filed for a US IPO worth up to $100 million. They detailed in their filings a strategy to roll cash into preclinical work, advancing the trials for two drugs targeting blood cancer and solid tumors and further testing the checkpoint inhibitor monalizumab, while also building a commercial infrastructure to market and capitalize on their trademark leukemia drug Lumoxiti.